P1.08-026 LUNG CANCER - Early and Late Outcomes of Surgical Patients of a New District Hospital: Topic: Epidemiologic Studies in Surgery for NSCLC

To compare surgical patient outcomes of a new district hospital with the expected results described in the literature. From March 2012 to December 2015, 288 lung cancer patients were treated in our hospital, of which 58 were operated on. All patients were discussed at a multidisciplinary team. The mean age at diagnosis was 64.6±9.2y yrs, being 69% males. At the time of diagnosis, 45 had history of smoking, 28 filled the criteria of COPD, 2 had history of tuberculosis, 2 had type 2 diabetes, 37 had history of cardiovascular disease, 8 had history of other cancer and 3 had chronic renal disease. As for tumor types, the majority was adenocarcinoma (34), followed by squamous cell (18), carcinoid tumor (3), SCLC (1), adenosquamous (1) and poorly differentiated lung cancer (1). One patient had 2 synchronous tumors and two patients developed a new type of tumor during follow-up. As for staging, the majority of patients were in clinical stage IA (20) and the rest distributed as follows: IB - 13 pts, IIA - 4 pts, IIB - 4 pts, IIIA - 10 pts, IIIB - 1 pt and IV - 6 pts. At the time of pathological staging 1 was up-staged and 1 down-staged. In stage IV patients, 4 surgeries were performed with palliative intent and 2 with curative intent. In 17.2% patients was given neo-adjuvant chemotherapy, and 44.8% received adjuvant chemotherapy. We performed 64 surgeries (41 lobectomies with lymphadenectomy (11 VATS); 6 bilobectomies; 3 pneumectomies; 6 wedge resections; 1 exploratory thoracotomy and 3 mediastinoscopies. There was no perioperative mortality. Eight patients had major complications (6 - post-operative pneumonia). The mean follow-up time was 21±11 months with an overall mortality of 15.5%. Stage related mortality: for stages IA and IB the overall survival was 100% with mean follow-up time of 23 months, in stage IIA the overall survival was 83.4% with mean follow-up time of 28 months, in stage IIB the overall survival was 75% with mean follow-up time of 24 months, in stage IIIA the overall survival was 70% with mean follow-up time of 20 months and in stage IV the overall survival was 33.3% with mean follow-up time of 18 months. These outcomes overlap those reported in recent data from the literature. Although our Hospital is a low/medium volume center for Lung Cancer we show with these data that with a dedicated multidisciplinary team it is possible to replicate the international results.